20年回顾:急诊研究中例外知情同意与知情同意豁免的使用
本研究回顾了20年使用例外知情同意(EFIC)或知情同意豁免(WIC)作为主要知情同意方式的已发表试验。通过MEDLINE、ClinicalTrials.gov等检索,共28项研究纳入分析,其中24项(86%)使用EFIC,4项使用WIC;最常见研究疾病为心脏骤停(10项)、失血性休克(6项)和创伤性脑损伤(5项)。预研究法规要求的报告情况:FDA研究性新药/器械豁免申请(14项,50%)、社区咨询(13项,46%)、公开披露(10项,36%)、伦理委员会要求的退出程序(7项,25%);仅13项(46%)出版物描述了使用EFIC/WIC的必要性依据。结论认为EFIC/WIC法规促进了针对毁灭性危及生命疾病的研究进展,但发表中对法规预研究要求和EFIC/WIC使用依据的报告缺乏一致性和严谨性。
要点
- 28项使用EFIC或WIC的已发表试验中,24项(86%)使用EFIC,4项使用WIC。
- 研究最多的疾病为心脏骤停(10项)、失血性休克(6项)、创伤性脑损伤(5项)。
- 预研究法规要求报告率:FDA研究性新药/器械豁免申请14项(50%)、社区咨询13项(46%)、公开披露10项(36%)、伦理委员会要求的退出程序7项(25%)。
- 仅13项(46%)出版物描述了使用EFIC/WIC的必要性依据(至少提及8项既定标准之一)。
- 作者认为,在研究本身呈现中更好地说明使用EFIC/WIC的必要性,可能教育普通医学界并减少对法规是否被正确应用的担忧。
适用人群与场景
- 因急性病情缺乏能力提供有意义的前瞻性知情同意参与临床研究的患者。
研究设计与关键结果
- 研究类型为20年已发表试验的回顾性审查,通过MEDLINE、ClinicalTrials.gov、向急诊与复苏研究人员及急性护理研究网络主要研究者查询、临床综述论文及FDA档案查询识别研究。
- 共识别45项可能合格研究,11项正在进行(尚无数据)、4项已完成(无发表或数据)、2项未使用EFIC或WIC,剩余28项纳入分析。
- 28项研究中24项(86%)使用EFIC,4项使用WIC;最常见研究疾病为心脏骤停(10项)、失血性休克(6项)、创伤性脑损伤(5项)。
- 预研究法规要求报告:FDA研究性新药/器械豁免申请(针对FDA监管研究)14项(50%)、社区咨询13项(46%)、公开披露10项(36%)、伦理委员会要求的退出程序7项(25%)。
- 使用EFIC/WIC的必要性依据(定义为提及8项既定标准中至少一项)在13项(46%)出版物正文中描述。
证据类型、等级与局限
- 证据类型:20年已发表试验的回顾性审查,数据以描述性方式呈现。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,由于无知情同意的研究是伦理敏感问题且未被广泛理解,在研究呈现中更好地说明其必要性可能教育普通医学界并减少对法规是否被正确应用的担忧。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Due to the acuity and time-sensitive needs of their clinical condition, patients presenting with certain emergent pathologies may lack capacity to provide meaningful prospective informed consent to participate in clinical research. For these reasons, these populations have often been excluded from research investigations. To mitigate this, regulations allowing exception from informed consent (EFIC; 21 CFR 50.24) or waiver of informed consent (WIC; 45 CFR 46.101) were developed in 1996. The purpose of this study was to identify trends in the utilization of EFIC and WIC in emergency research. We also sought to describe the disclosure of necessary prestudy regulatory requirements and justification for the use of EFIC/WIC as reported in completed EFIC/WIC clinical trials.
METHODS: This study is a review of 20 years of published trials using EFIC or WIC as the primary method of patient consent. Studies were identified using a MEDLINE search; ClinicalTrials.gov; queries to emergency and resuscitation researchers, research directors, department chairs, and principal investigators of acute care research networks; clinical review papers; and a query of the Federal Drug Administration (FDA) docket. All eligible studies were reviewed by three investigators and study data of interest were abstracted. Data are presented descriptively.
RESULTS: We identified 45 potentially eligible studies; 11 were ongoing (with no data yet available), four were completed (with no publications or data available), and two did not use EFIC or WIC. Of the remaining 28 studies, 24 (86%) used EFIC and four used WIC. The most common pathologies under study were cardiac arrest (10), hemorrhagic shock (six), and traumatic brain injury (five). Completion of the prestudy regulatory requirements was reported as follows: FDA investigational new drug/investigational device exemption application (for FDA regulated studies; 14, 50%), community consultation (13, 46%), public disclosure (10, 36%), and opt-out procedures if requested by the institutional review board (seven, 25%). The justification of the need for the use of EFIC or WIC in the reported clinical trial, as defined as mention of at least one of the eight established criteria, was described in the text of 13 (46%) publications.
CONCLUSIONS: Since their implementation in 1996, the EFIC/WIC regulations have allowed progress in research aimed at determining optimal care for devastating life-threatening conditions. However, consistent and rigorous report of regulatory prestudy requirements and justification of the use of EFIC/WIC is lacking in clinical trial publications or on websites such as ClinicalTrials.gov. Since research without consent is an ethically sensitive issue and not widely understood, better justification of its needs within the presentation of the research itself may educate the general medical community and also reduce concerns about whether or not the regulations are being properly applied.
参考来源
- Klein L, Moore J, Biros M, et al. A 20-year Review: The Use of Exception From Informed Consent and Waiver of Informed Consent in Emergency Research. Acad Emerg Med. 2018. PMID: 29679443. doi:10.1111/acem.13438
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。